top of page
Prostacyclin analogues for CTEPH?
This systemic review summarized the data from six studies that examined whether prostacyclin analogues are safe and useful when used to...
PHA Canada
May 261 min read
Â
Â
Â


Rare But Not Alone: What Canada’s New Drug Strategy Means for People with Pulmonary Arterial Hypertension
Living with a rare disease can feel like walking an unmarked path—isolated, uncertain, and overlooked. For those with pulmonary arterial...
PHA Canada
May 132 min read
Â
Â
Â
Some PAH patients on sotatercept can stop taking prostacyclin analogues
In a small study of 34 pulmonary arterial hypertension (PAH) patients taking triple therapy plus sotatercept, some were able to stop...
PHA Canada
May 121 min read
Â
Â
Â


Sotatercept Is Not Just Another Medication
My name is Cindy Hayman, and I have been living with Pulmonary Arterial Hypertension (PAH) for the past seven years. I am classified as a...
PHA Canada
May 82 min read
Â
Â
Â
PHA Canada Marks World Pulmonary Hypertension Day with National Advocacy Events Calling for Timely Access to Treatment
On May 5, World Pulmonary Hypertension Day , the Pulmonary Hypertension Association of Canada (PHA Canada)Â is calling for urgent action...
PHA Canada
May 52 min read
Â
Â
Â


Left-Sided Heart Disease & Pulmonary Hypertension
I was diagnosed with Pulmonary Hypertension in 2019. After tests & procedures, it was determined I likely had group 2 and 3 PH. Group 2...
Dawn Clarke - patient
May 13 min read
Â
Â
Â
Poverty and isolation are associated with worse pulmonary hypertension outcomes
A 2024 study looked at the association between socioeconomic disadvantage and pulmonary hypertension. In one New York hospital system,...
PHA Canada
Apr 281 min read
Â
Â
Â
New Report Exposes Gaps in BC Medication Coverage
The 2025 BC Medication Coverage Report  is here—and it reveals serious gaps in access to life-saving medications across the province....
PHA Canada
Apr 141 min read
Â
Â
Â
Some PH patients with interstitial lung disease may benefit from oral PAH drugs
Medications for pulmonary arterial hypertension (PAH) are not approved for use in patients with pulmonary hypertension due to...
PHA Canada
Apr 141 min read
Â
Â
Â
ZENITH results published: sotatercept is effective for high-risk PAH patients
The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...
PHA Canada
Apr 81 min read
Â
Â
Â
Sotatercept is Now in Active Negotiation at pCPA
There has been significant progress in making sotatercept available to those who need it. Just two months after Health Canada approved it...
PHA Canada
Apr 41 min read
Â
Â
Â
Main pulmonary artery diameter predicts risk in PAH patients
Researchers wanted to know whether an enlarged pulmonary artery could independently predict risk in pulmonary arterial hypertension (in...
PHA Canada
Mar 311 min read
Â
Â
Â


Two tips for tax season
Tax season is upon us! The pulmonary hypertension community brought two tips to our attention. First, the usual disclaimer: we are not...
PHA Canada
Mar 251 min read
Â
Â
Â
Plain-language summary available for the TORREY seralutinib study
Seralutinib is a molecule that blocks inflammation, cell proliferation, and scarring responsible for pulmonary arterial hypertension. The...
PHA Canada
Mar 171 min read
Â
Â


A Canadian Initiative: Exploring Adult Pulmonary Hypertension
New Report Sheds Light on Pulmonary Hypertension in Canada Respiplus has just released a groundbreaking report, A Canadian Initiative:...
PHA Canada
Mar 131 min read
Â
Â
Â
Did you know Canada has a Caregiver Tax Credit?
Many people know about Canada’s Disability Tax Credit, but did you know that there is also a non-refundable tax credit for caregivers? If...
PHA Canada
Mar 41 min read
Â
Â
Â
PAH patients who skip treatment don't do as well as patients who adhere to their treatment plan
In a study of data from the Pulmonary Hypertension Association Registry in the US, researchers looked at who was more likely to skip...
PHA Canada
Mar 31 min read
Â
Â


New Faces, Lasting Connections: My First PH Conference Experience
The 2024 Pulmonary Hypertension Patient Symposium in Calgary was my first rodeo, as it were. I started dating my partner Tarya in the...
Simon Goring
Feb 193 min read
Â
Â
Â
Newly diagnosed PAH patients on triple therapy have fewer hospitalizations vs. double therapy
A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an...
PHA Canada
Feb 181 min read
Â
Â
HYPERION sotatercept study has positive results, stops early
The HYPERION study examined whether adding sotatercept to other therapies for recently diagnosed patients with pulmonary arterial...
PHA Canada
Feb 101 min read
Â
Â
Â
bottom of page
